focus -WSS

focus

author：Wikipedia 2025-09-06 03:55:19 - browse：921

Adam's take main illustration — Molly Ferguson/STAT

This week, an encouraging turnaround for Ocular Therapeutix, a chat with Alnylam’s CEO defending changes to the HELIOS-B study and talking up its hypertension treatment, and quick takes on Amylyx and obesity stocks.

A Worst CEO gets some much-needed help

For most of last year, Ocular Therapeutix CEO Antony Mattessich promised shareholders that he was close to nailing down a lucrative pharma partnership that would pay for late-stage clinical trials of the company’s treatments for degenerative eye diseases. The deal never happened. I heard from many Ocular investors who were frustrated and angry about Mattesich’s poor job performance. He ended up earning a spot last year on my worst biopharma CEO list. It was an easy pick.

On Thursday, Ocular announced a meaningful “leadership update.” Mattessich is still the CEO, but let’s just say the company’s board decided to surround him with new executives and retinal experts with proven track records of getting stuff done.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： With Roe v Wade overturned, abortion providers work to adapt

hotspot

entertainment

WSS

CDC overhauls leadership of center that led response to Covid

What we owe ALS patients — and why one company fell short

Covid's long

European officials brace for rough respiratory virus season

Genentech weighs delaying cancer therapy after drug pricing law

Kim Kardashian sparks debate on benefits of full

leisure time

focus

A Worst CEO gets some much-needed help

focus

Affirmative action in medical school literally saved lives

With Roe v Wade overturned, abortion providers work to adapt

In Memoriam: Notable people who died in 2023

Trump, Nauta plead not guilty to new classified docs charges but De Oliveira still not arraigned

Dobbs anniversary: the lost opportunity of abortion as health care

European officials brace for rough respiratory virus season

How one medical school became remarkably diverse

The history of OxyContin, told through Purdue Pharma documents

Jerome Adams on the need for new antivirals for Covid

O'Shea Sibley was killed after expressing queer joy by voguing, activists say

knowledge

Some top drug companies are starting to take action on climate

IVG is promising — but it won’t replace IVF quite yet

Congress extends some pandemic preparedness programs

WHO recommends second malaria vaccine

White House drug shortages task force keeps mum with Congress

Study points to new risk in gene therapy death of Terry Horgan

explore

hotspot

entertainment

Wikipedia